Kellie S. Rath

Riverside Methodist Hospital — United States

Medicine · Health Sciences

14h-index712citations85works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(33), Ovarian cancer diagnosis and treatment(22), Virus-based gene therapy research(11), Herpesvirus Infections and Treatments(8), Endometrial and Cervical Cancer Treatments(8)

Publications85 total

Efficacy and Safety of <i>Ayurveda</i> Compound Formulations in <i>Sthoulya</i> (Obesity) Management: A Multi-centric Clinical Trial
Journal of Natural Remedies·2025· 2 citedOpen Access
Treatment of Ovarian Clear Cell Carcinoma: A Case of Successful Management With Targeted Therapies
Case Reports in Obstetrics and Gynecology·2025Open Access
Supplementary Tables 1 - 2 from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
2023Open Access
Data from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
2023Open Access
Outcomes of the "BRCA Quality Improvement Dissemination Program": An initiative to improve patient receipt of cancer genetics services at five health systems
Gynecologic Oncology·2023· 3 citedOpen Access
Data from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
2023Open Access
Figure S1 and Table S1. from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
2023Open Access
Supplementary Figures 1 - 2 from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
2023Open Access
Data from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
2023Open Access
Supplementary Figure and Table Legends. from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
2023Open Access
Figure S1 and Table S1. from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
2023Open Access
Data from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
2023Open Access
Supplementary Figures 1 - 2 from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
2023Open Access
Supplementary Tables 1 - 2 from Bortezomib-Induced Unfolded Protein Response Increases Oncolytic HSV-1 Replication Resulting in Synergistic Antitumor Effects
2023Open Access
Supplementary Figure and Table Legends. from Doxorubicin Synergizes with 34.5ENVE to Enhance Antitumor Efficacy against Metastatic Ovarian Cancer
2023Open Access
Supplementary Figure 4 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023Open Access
Supplementary Figure 11 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023Open Access
Supplementary Figure 10 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023Open Access
Supplementary Figure 2 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023Open Access
Supplementary Figure 6 from HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer
2023Open Access
page 1 of 5Next →

Frequent Co-authors

David E. Cohn(24), Georgia A. McCann(20), Shan K. Naidu(16), Periannan Kuppusamy(16), Karuppaiyah Selvendiran(15), Brent J. Tierney(14), Peter J. Houghton(14), Kálmán Hideg(14), Pushpa Lata(13), Hemant K. Bid(13), Brian K. Rivera(13), Adam C. ElNaggar(13), Aine Clements(11), Verónica Bravo(11), Gustavo Leone(10), Ritu Salani(8), Jeffrey M. Fowler(7), David M. O’Malley(7), Eric Eisenhauer(7), Floor Backes(7)